Story

BeiGene Shares Climb on Strong Q2 Results and Solid Tumor Pipeline Progress

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20262 min read
BeiGene Shares Climb on Strong Q2 Results and Solid Tumor Pipeline Progress
Text size
Background

Shares of biotechnology company BeiGene (06160.HK) gained nearly 4% in Hong Kong trading after the company announced robust financial results for the second quarter, highlighted by strong revenue growth and advancements in its solid tumor drug pipeline.

Strong Q2 Performance

In its earnings report released on August 6, BeiGene disclosed a 30% year-over-year increase in global total revenue, reaching approximately $1.705 billion for the second quarter. The company's profitability also saw a substantial rise, with GAAP net profit surging 151% to about $237 million and adjusted net profit growing 76% to approximately $444 million.

Product revenue, which totaled $1.7 billion for the quarter, was primarily driven by the company's oncology portfolio. Key sales figures include:

  • Brukinsa®: Global sales of the cancer treatment hit $1.2 billion, a 31% increase from the prior year, with U.S. sales contributing $893 million.
  • Tislelizumab: Global sales for this antibody treatment reached $229 million, up 18% year-over-year.
  • Amgen-licensed products: Sales from this partnership grew 25% to $157 million.

Analyst Upgrade and Pipeline News

Sample IUX Markets – In-articleAd

Following the earnings release, a research report from CLSA highlighted BeiGene's progress in the solid tumor field. The report noted that the company has completed a registrational expansion study in China for its bispecific antibody, BGB-B2033, in late-line hepatocellular carcinoma (liver cancer). BeiGene also plans to initiate a global Phase 3 clinical trial for the drug in second-line hepatocellular carcinoma in the second half of the year.

Citing the company's strong global commercial performance and late-stage solid tumor pipeline, CLSA upgraded its financial forecasts for BeiGene. The firm raised its sales estimates for 2026, 2027, and 2028 by 4%, 3.3%, and 3.2%, respectively, while increasing its net profit forecasts by 23.5%, 12.5%, and 7.3% for the same years.

Market Reaction

In response to the positive earnings and pipeline update, BeiGene's shares on the Hong Kong Stock Exchange rose 3.66% to close at HK$206.8, with a trading turnover of HK$362 million. In addition to its Hong Kong listing, BeiGene is also traded on the Nasdaq (BGNE) in the United States and the STAR Market in Shanghai.

Read next

More on Stocks
Back to latest news

LATEST